32701-02-3Relevant articles and documents
Synthesis, in vitro antiproliferative activity and DNA-interaction of benzimidazoquinazoline derivatives as potential anti-tumor agents
Dalla Via, Lisa,Gia, Ornella,Marciani Magno, Sebastiano,Da Settimo, Antonio,Marini, Anna Maria,Primofiore, Giampaolo,Da Settimo, Federico,Salerno, Silvia
, p. 159 - 167 (2001)
The synthesis of benzimidazoquinazoline derivatives bearing different alkylamino side chains is reported. All new compounds tested by means of an in vitro assay exhibit antiproliferative activity toward human tumor cell lines. The cytotoxic effect depends on the type of side chain inserted in the planar nucleus and in some cases it is comparable to that of the well-known drug ellipticine. In order to understand the mechanism of action of these compounds, the interaction with DNA has been investigated. Linear flow dichroism measurements allowed us to verify the formation of a molecular complex with DNA and the corresponding geometry of interaction. Intrinsic binding constants have also been evaluated by performing fluorimetric titrations.
Targeting the KRAS oncogene: Synthesis, physicochemical and biological evaluation of novel G-Quadruplex DNA binders
Amato, Jussara,Barresi, Elisabetta,Biroccio, Annamaria,Caterino, Marco,D'Amore, Vincenzo Maria,D'Aria, Federica,Da Settimo, Federico,De Leo, Marinella,Di Leva, Francesco Saverio,Giancola, Concetta,Marinelli, Luciana,Marini, Anna Maria,Novellino, Ettore,Pompili, Luca,Russomanno, Pasquale,Salerno, Silvia,Salgado, Gilmar F.,Shirasawa, Senji,Taliani, Sabrina,Zizza, Pasquale
, (2020)
The oncogene KRAS is involved in the pathogenesis of many tumors such as pancreatic, lung and colorectal cancers, thereby representing a relevant target for the treatment of these diseases. The KRAS P1 promoter contains a nuclease hypersensitive, guanine-rich sequence able to fold into a G-quadruplex motif (G4). The stabilization of this G4 structure by small molecules is emerging as a feasible approach to downregulate KRAS expression. Here, a set of novel stabilizing molecules was identified through a virtual screening campaign on the NMR structure of the 22-mer KRAS G4. The most promising hits were then submitted to structure-activity relationships studies which allowed improving their binding affinity and selectivity over double helix DNA and different G4 topologies. The best derivative (19) underwent fluorescence titration experiments and further computational studies to disclose its binding mechanism to KRAS G4. Finally, biological assays showed that this compound is capable to reduce the viability of colorectal cancer cells in which mutated KRAS acts as a driver oncogene. Thus, 19 might represent the prototype of a new class of drugs for the treatment of tumors that, expressing mutated forms of KRAS, are refractory to current therapeutic regimens.
